Celsus Therapeutics Announces Appointment of Pablo Jimenez, M.D., to Chief Medical Officer

Published: Oct 24, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK and LONDON, Oct. 24, 2013 (GLOBE NEWSWIRE) -- Celsus Therapeutics (OTCQB:CLSXY), an emerging growth, development-stage biopharmaceutical company, announces the appointment of Pablo Jimenez, M.D., to the position of Chief Medical Officer. This appointment reflects Celsus' continued growth as the company advances the development of its lead clinical asset, MRX-6, a non-steroidal anti-inflammatory cream for the treatment of eczema and other skin inflammatory disorders.

Help employers find you! Check out all the jobs and post your resume.

Back to news